Insmed received FDA approval for Brinsupri (brensocatib), the first therapy for non-cystic fibrosis bronchiectasis, addressing neutrophilic inflammation to reduce exacerbations. The approval impacts approximately 500,000 patients in the U.S. and millions globally. The company’s shares surged 17% post-announcement, with several analysts forecasting blockbuster sales potential. Brinsupri’s development was supported by Phase III ASPEN trial data demonstrating efficacy and safety.